Glaukos (NYSE:GKOS) Director Gilbert Kliman Sells 2,500 Shares

Glaukos Corporation (NYSE:GKOS) Director Gilbert Kliman sold 2,500 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total transaction of $475,000.00. Following the completion of the transaction, the director directly owned 37,406 shares in the company, valued at $7,107,140. The trade was a 6.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Glaukos Trading Down 2.3%

GKOS opened at $185.25 on Friday. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $191.62. The business has a fifty day moving average price of $156.20 and a 200 day moving average price of $131.24. The stock has a market capitalization of $10.93 billion, a price-to-earnings ratio of -57.00 and a beta of 0.78. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The company had revenue of $185.61 million during the quarter, compared to the consensus estimate of $150.93 million. During the same quarter in the prior year, the firm posted ($0.24) earnings per share. Glaukos’s revenue for the quarter was up 49.6% on a year-over-year basis. Sell-side analysts expect that Glaukos Corporation will post -0.35 earnings per share for the current fiscal year.

Glaukos News Summary

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: BTIG raised its price target to $202 from $193 and maintained a “Buy” rating, implying about 9% upside from the referenced $185.25 price. The upgrade reflects continued confidence in Glaukos’ growth outlook. Benzinga report
• Positive Sentiment: Analyst estimates from Zacks Research were raised broadly, including FY2027 EPS to $0.45 from $0.38 and FY2028 EPS to $1.70 from $1.56. Forecasts for several 2027 and 2028 quarters were also increased, signaling expectations for a transition toward stronger earnings. Glaukos analyst estimates
• Positive Sentiment: Glaukos’ iDose TR glaucoma implant and the Epioxa launch are driving record growth and contributed to higher 2026 guidance. Investors are also responding to the company’s expanding ophthalmology platform, product pipeline and potential for margin expansion. Zacks growth outlook article
• Neutral Sentiment: The company recently reported revenue of $185.6 million, up 49.6% year over year, and a quarterly loss of $0.14 per share that was better than expected. Glaukos remains unprofitable, but analysts expect positive EPS in future periods as revenue scales.
• Negative Sentiment: Director Gilbert H. Kliman sold 2,500 shares for approximately $475,000 at an average price of $190. The sale reduced his direct ownership by 6.26%, although he still held 37,406 shares afterward. SEC insider trading filing

Analysts Set New Price Targets

GKOS has been the subject of a number of research analyst reports. William Blair restated an “outperform” rating on shares of Glaukos in a research report on Tuesday, May 26th. Stifel Nicolaus increased their price target on shares of Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Citigroup raised their price target on Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Needham & Company LLC upped their price objective on Glaukos from $150.00 to $201.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Finally, HC Wainwright increased their price objective on Glaukos from $168.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $178.08.

Institutional Investors Weigh In On Glaukos

Several hedge funds have recently made changes to their positions in GKOS. BlackRock Inc. acquired a new position in shares of Glaukos during the 2nd quarter valued at about $1,333,318,000. Jupiter Topco LLC acquired a new stake in shares of Glaukos in the second quarter worth approximately $679,614,000. Primecap Management Co. CA purchased a new stake in Glaukos in the second quarter valued at approximately $424,969,000. Janus Henderson Group PLC increased its position in Glaukos by 77.2% during the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock worth $575,844,000 after purchasing an additional 2,329,608 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Glaukos by 209.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier’s stock worth $152,476,000 after purchasing an additional 913,458 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.